November 18, 2025
Join us at the Future of the Microbiome 2025 Winter Summit, a leading virtual event that brings together industry experts to explore the next wave of microbiome innovations. We’re proud to once again be the champion sponsors of this year’s summit.
Future of the Microbiome offers a cross-disciplinary look at the latest developments in prebiotics, probiotics, postbiotics, and live biotherapeutics, highlighting both the science and its real-world applications. We look forward to connecting with peers and contributing to the continued evolution of microbiome research and strategy.
Our Director of Scientific Affairs, Stephanie-Anne Girard, will be attending the event to deliver a presentation titled “The Clinical Potential of Postbiotics: Evidence, Applications, and Design Considerations.”
In this session, she will cover:
-
The science behind postbiotics - what they are, how they differ from other “biotics,” and why their stability and safety are important.
-
Emerging evidence across key health areas including the gut–brain axis, gut, skin, and metabolic health.
-
Advantages for clinical research, such as standardized dosing, regulatory clarity, and simplified trial logistics.
-
Practical insights into clinical trial design considerations for this rapidly growing category of bioactive compounds.
Interested in attending? Click the link below.
sign up now
Attending from the SGS Nutrasource Team
Stéphanie-Anne Girard, PhD
Director, Scientific Affairs
Stéphanie-Anne Girard, PhD, brings over 15 years of natural health product/dietary supplement and pharmaceutical clinical research experience. Dr. Girard’s industry work experience includes a leadership position as Clinical Program Manager at Lallemand Health Solutions (LHS) where she oversaw study design and execution of clinical trials on probiotics, working closely with universities, CROs, private research sites, and KOLs. During this time, she published numerous scientific articles in peer-reviewed journals and has presented at many international conferences and scientific meetings. More recently, Dr. Girard has managed clinical operations teams at ICON Strategic Solutions where she was assigned to Merck Canada.
Dr. Girard holds a PhD in Nutritional Sciences from the University of Florida, a Masters’ degree in Pharmacology from the University of Montreal and a BSc in Microbiology and Immunology from McGill University. Additionally, she completed a Post–Doctoral degree through an Industrial R&D Fellowship Program from the Natural Sciences and Engineering Research Council of Canada (NSERC) in collaboration with LHS. Her academic training focused on pre-clinical research investigating the effects of probiotics on post-myocardial infarction depression, which resulted in an understanding of the effect of probiotics on the kinetics of biochemical and physiological cerebral changes following a myocardial infarction. In collaboration with Sponsors from the food industry, she also oversaw several clinical studies investigating prebiotics, specifically, galactooligossacharide (GOS), immunity and digestive health in older adults during cold/flu season.
Skip to main content